qax-576
mAbexperimental
Clinical trial activity
12 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00417196)
Timeline
Indications
Mechanism of action
- Interleukin-13INHIBITOR
IL13 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109465 ↗
Also known as
- qax576
- qax-576
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01355614 | Phase 2 | Jun 1, 2011 | Novartis |
| NCT01266135 | Phase 2 | Dec 1, 2010 | Novartis |
| NCT01568762 | Phase 1 | Oct 1, 2010 | Novartis |
| NCT01130064 | Phase 2 | May 1, 2010 | Novartis |
| NCT01022970 | Phase 2 | Nov 1, 2009 | Novartis |
| NCT00940160 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2009 | Novartis |
| NCT00987545 | Phase 2 | Jun 1, 2009 | Dermatology Consulting Services, High Point NC, Novartis, TKL Research, Virginia Clinical Research, Inc. |
| NCT00598104 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2008 | Novartis |
| NCT00584584 | Phase 2 | Dec 1, 2007 | Novartis |
| NCT00581997 | Phase 2 | Dec 1, 2007 | Novartis |
| NCT00532233 | Phase 2 | Sep 1, 2007 | Novartis |
| NCT00417196 | Phase 1 | Dec 1, 2006 | Novartis |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 12 | 12 | 2 | 2006 |
| Dermatology Consulting Services, High Point NC | Academic/Hospital | 1 | 0 | 1 | 2009 |
| TKL Research | For profit | 1 | 0 | 1 | 2009 |
| Virginia Clinical Research, Inc. | For profit | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1